Fig. 4: Clinical and patient-reported response across PsA domains by treatment arm. | Nature Medicine

Fig. 4: Clinical and patient-reported response across PsA domains by treatment arm.

From: Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Fig. 4: Clinical and patient-reported response across PsA domains by treatment arm.

a, Proportion of participants achieving MDA over time through week 24 (ITT–NRI). *P < 0.05 versus PBO (P = 0.022 for SLK 60-mg WI at week 12). Two-sided P values were estimated using a logistic regression model including fixed effects for treatment and stratification factors (sex and prior biologic exposure). Statistical analyses for these endpoints were exploratory, and P values are nominal (no adjustments to P values or significance levels were performed). NRI, except for patients who switched treatment due to the lack of joint response or for patients in the United States who completed the study at week 12, where the last observation during part A was carried forward. MDA is defined as meeting at least five of the following criteria: TJC68 ≤ 1, SJC66 ≤ 1, PASI ≤ 1 or psoriasis ≤ 1% of BSA, PtAAP ≤ 15, PGA ≤ 20, HAQ-DI ≤ 0.5 and LEI ≤ 1. b, Mean PsAID-12 item scores at baseline, week 12 and week 24. aLOCF imputation was used for patients who switched treatment due to the lack of joint response or for patients in the United States who completed the study at week 12, where the last observation during part A was carried forward. All other missing data were imputed using LOCF. Data represent mean values. LOCF, last observation carried forward.

Back to article page